st-1898
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 7, 2023 (NCT06127238)
Timeline
Indications
Mechanism of action
KDR antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07252661 | Phase 1 | Jan 31, 2026 | AccSalus Biosciences, Inc. |
| NCT06359847 | Phase 2 | Nov 15, 2023 | Chinese Academy of Medical Sciences, SciTech Development, LLC |
| NCT06359860 | Phase 1/Phase 2 (Phase 2) | Nov 7, 2023 | Peking University, SciTech Development, LLC |
| NCT06127238 | Phase 1/Phase 2 (Phase 2) | Feb 7, 2023 | Peking University, SciTech Development, LLC |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SciTech Development, LLC | For profit | 3 | 3 | 1 | 2023 |
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2023 |
| AccSalus Biosciences, Inc. | For profit | 1 | 1 | 1 | 2026 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1